abicipar-pegol（allergan）是一种血管内皮生长因子（vegf）靶向的锚蛋白重复序列蛋白（darpin）。darpins被提议提供单克隆抗体的许多优点，同时提供其他一些潜在的优点，包括对靶点的高亲和力、低免疫原性、可调节的药代动力学曲线和简单的制造。abicipar-pegol是一种高效的血管内皮生长因子拮抗剂，其眼半衰期长达两周左右，理论上可以提供与目前湿性amd中使用的血管内皮生长因子抑制剂相似的视觉效果，治疗所需的玻璃体腔注射更少。

分子合作伙伴最初开发了abicipar pegol作为其darpins管道组合的一部分。2011年5月，Molecular Partners和Allergan签订了一项许可协议，根据该协议，Allergan获得了Abicipar Pegol在所有眼科适应症中的全球权利，以换取4500万美元的预付款、3.75亿美元的里程碑付款以及该药未来销售的版税。

Allergan已经将Abicipar-Pegol发展到III期，在湿性年龄相关性黄斑变性（AMD）中的关键试验正在进行中。阿比西帕尔聚乙二醇也正在评估治疗糖尿病黄斑水肿（二甲醚）。Allergan预计，从2020年起，将首次商用Abicipar Pegol用于湿性AMD，随后将从2022年扩展到二甲醚。

Abicipar pegol (Allergan) is a vascular endothelial growth factor (VEGF)-targeted designed ankyrin repeat protein (DARPin). DARPins are proposed to provide many of the benefits of monoclonal antibodies while offering several other potential advantages including a high affinity for targets, low immunogenicity, an adjustable pharmacokinetic profile, and simple manufacturing. Abicipar pegol has been specifically shown to be a highly potent VEGF antagonist with a long ocular half-life of about two weeks, theoretically allowing it to provide similar visual outcomes to VEGF inhibitors currently used in wet AMD with fewer intravitreal injections needed for treatment.

Molecular Partners originally developed abicipar pegol as part of its pipeline portfolio of DARPins. In May 2011, Molecular Partners and Allergan entered a licensing agreement, under which Allergan received global rights for abicipar pegol in all ophthalmic indications in exchange for $45m in upfront payments, $375m in milestone payments, and royalties on future sales of the drug.

Allergan has progressed abicipar pegol to Phase III development, with pivotal trials ongoing in wet age-related macular degeneration (AMD). Abicipar pegol is also being evaluated for the treatment of diabetic macular edema (DME). Allergan anticipates first commercial availability of abicipar pegol for wet AMD from 2020, with a later expansion to the DME indication from 2022